Your Nose May Hold The First Clues That Alzheimer's Is Coming

A Nasal Swab Might One Day Help Detect Dementia Earlier

Losing your sense of smell is one of the earliest known warning signs of Alzheimer’s disease. Now, a new study suggests the tissue behind that lost sense might hold something even more valuable: a biological window into the disease before any symptoms appear.

Researchers at Duke University found that a minimally invasive brush biopsy of the olfactory cleft, a small patch of scent-detecting tissue at the top of the nasal cavity, can capture immune and neurological changes that closely mirror those seen in the spinal fluid of Alzheimer’s patients. More significantly, those changes appear even in people who have no memory or thinking problems at all, but whose spinal fluid already carries the early chemical fingerprints of disease. The nose, it turns out, may offer a new window into Alzheimer’s at its earliest stages.

“Ultimately, these findings position OE sampling as a practical strategy for studying AD pathobiology at its earliest, most treatable stage,” the authors wrote in their paper, published in Nature Communications.

What a Nasal Swab Has to Do With Alzheimer’s Disease

To understand why the nose matters here, a bit of anatomy helps. Tucked into the upper nasal cavity, the olfactory epithelium is packed with specialized neurons that detect odors and relay signals directly to the brain. Those neurons connect to the entorhinal cortex, a key memory-processing region and one of the first brain areas damaged in Alzheimer’s. Cerebrospinal fluid, which bathes the brain and spinal cord, also drains through nearby lymphatic pathways that pass this region, meaning immune cells in nasal tissue are continuously exposed to biochemical signals from the brain itself.

Prior research had already shown that olfactory neurons can accumulate the same amyloid plaques and tau tangles that define Alzheimer’s in the brain. What had never been done was analyzing this tissue from living people across different disease stages using gene-sequencing tools sensitive enough to read individual cells.

22 Patients, One Quick Swab, and Over 220,000 Cells

Duke researchers recruited 22 participants across three groups. Six were healthy controls. Seven had clinical Alzheimer’s disease, with both abnormal biomarkers and cognitive impairment. Nine were pre-clinical, meaning cognitively normal adults whose spinal fluid already showed the protein imbalances that signal Alzheimer’s is quietly developing.

Each participant underwent an awake, no-sedation procedure in which a small brush, guided by a thin nasal camera, was gently rotated inside the olfactory cleft to collect surface cells. Those cells were then analyzed using single-cell RNA sequencing, a technology that reads the gene activity of every individual cell. Across all 22 participants, the team catalogued 220,509 cells, capturing T cells, macrophages, dendritic cells, and olfactory sensory neurons. Because neurons were not successfully collected from every biopsy, the neuronal analysis was conducted on a subset of 18 subjects.

Immune Alarm Bells Going Off Before Symptoms Appear

In the pre-clinical group, olfactory tissue already showed a pattern of immune activation closely resembling patterns previously reported in spinal fluid studies of Alzheimer’s patients. That was the study’s most notable finding.

A type of immune cell called CD8 T cells, which help drive inflammation, were significantly more activated in pre-clinical Alzheimer’s subjects than in healthy controls, with 13.4% of memory CD8 T cells showing activation markers compared to 4.1% in controls. A separate technique called flow cytometry, which identifies cell types by their surface proteins, confirmed this independently. Immune cells resembling microglia, the brain’s own immune sentinels, also showed heightened inflammatory activity in both the pre-clinical and clinical groups.

Olfactory sensory neurons showed altered activity in genes linked to inflammation and how brain cells handle fats and stress. One gene, AKR1B1, was elevated in both disease groups and encodes an enzyme that prior research has linked to the microglial activation triggered by amyloid buildup. Another, CERT1, showed reduced activity in both groups and is involved in a cellular process whose disruption has been tied to amyloid accumulation and neuroinflammation in Alzheimer’s models.

Could a Nasal Swab Help Diagnose Alzheimer’s Early?

When the researchers tested whether biopsy gene-activity patterns could distinguish Alzheimer’s patients from healthy controls, the results were encouraging. A combined score drawn from both immune and neuronal gene patterns achieved an area under the curve of 0.81, a standard accuracy measure where 1.0 is perfect and 0.5 is chance. That score correlated significantly with the cerebrospinal fluid amyloid ratio but not with cognitive test scores or tau protein levels, a pattern consistent with changes that predate cognitive decline.

Blood-based Alzheimer’s tests, including a recently FDA-approved plasma assay, have advanced considerably in recent years. Those tests primarily reflect protein changes linked to disease. Olfactory tissue, sitting at a direct neural interface with the brain, may reveal early immune and cellular changes that occur alongside or before those protein changes.

“Endoscopic olfactory-cleft brush biopsy could provide a feasible and repeatable way to sample accessible neuroepithelium in living humans at any disease stage,” the authors wrote.

With only 22 participants, the current work is a proof-of-concept that establishes feasibility, not diagnostic readiness. Larger, prospective studies pairing nasal biopsies with spinal fluid samples, brain imaging, and long-term follow-up will be needed before this approach enters clinical practice. Whether nasal tissue changes are a downstream consequence of early brain disease, an independent parallel process, or both also remains unresolved.

A disease that can silently progress for a decade before diagnosis may point to a new early warning site, one potentially accessible with a brief, minimally invasive swab-like procedure at a specialist’s office. With at-home nasal swab kits becoming more commonplace for health diagnoses, could we one day perform this biopsy ourselves and simply send it to the lab? It’s estimated that dementia cases could triple worldwide by 2050, making the potential for such a medical advance to have massive implications for Alzheimer’s prevention.

---

Disclaimer: This article is based on an early-stage research study published in a peer-reviewed journal. The findings reflect a proof-of-concept involving 22 participants and have not been clinically validated. The nasal biopsy method described is not currently available as a diagnostic tool, and no conclusions about individual risk or treatment should be drawn from this research. Readers with concerns about Alzheimer’s disease or cognitive health should consult a qualified medical professional.

---